Sandoz Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sandoz (Princeton, NJ): 70 reconciled FDA prescription therapies (1.4% 2025 to 2030 cliff risk), $1.10B 2024 CMS Part D & Medicaid spend, and 20 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterPrinceton, NJ
Reconciled FDA Portfolio Therapies70
2025 to 2030 Patent-Cliff Revenue Exposure1.4%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$1.10B
2024 Medicare Part D Spend$668.4M
2024 Medicaid Spend$433.8M
California HCAI SB 17 Filings20 WAC filings (max 107.0% 2-yr change)